Selected article for: "acute ARDS respiratory distress syndrome and cause infection"

Author: Somanath, Payaningal R.
Title: Is targeting Akt a viable option to treat advanced-stage COVID-19 patients?
  • Cord-id: bj6g95ub
  • Document date: 2020_7_1
  • ID: bj6g95ub
    Snippet: One of the primary reasons for high mortality in the advanced stage coronavirus disease-2019 (COVID-19) patients is the uncontrolled inflammation in the lungs leading to acute respiratory distress syndrome (ARDS). Controlling the pathological inflammation in the ARDS lungs without compromising the immune system's fight against the virus is indeed a daunting task. In this situation, an appropriate therapeutic target would be the one that will not only reverse the damaging inflammation and promote
    Document: One of the primary reasons for high mortality in the advanced stage coronavirus disease-2019 (COVID-19) patients is the uncontrolled inflammation in the lungs leading to acute respiratory distress syndrome (ARDS). Controlling the pathological inflammation in the ARDS lungs without compromising the immune system's fight against the virus is indeed a daunting task. In this situation, an appropriate therapeutic target would be the one that will not only reverse the damaging inflammation and promote resolution but also helps to check the root cause of the virus infection. Akt is a potential therapeutic target for the advanced stage COVID-19 patients; its inhibition will potentially suppress the pathological inflammation, cytokine storm, fibroproliferation, and platelet activation associated with COVID-19, and at the same time prevent scarring and promote resolution in injured lungs. As pharmacological inhibition of Akt has also been reported to inhibit ACE2 expression, a receptor for the virus entry into the lung cells, targeting Akt for COVID-19 looks a viable option.

    Search related documents:
    Co phrase search for related documents
    • ace inhibitor and acute respiratory distress syndrome: 1, 2, 3, 4, 5
    • ace inhibitor and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • ace inhibitor and lung damage: 1
    • ace inhibitor and lung disease: 1
    • ace inhibitor and lung infection: 1
    • ace inhibitor and lung inflammation: 1
    • ace inhibitor and lung injury: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and adoptive transfer: 1, 2
    • acute ards respiratory distress syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung damage limit: 1
    • acute ards respiratory distress syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung disease research: 1
    • acute ards respiratory distress syndrome and lung epithelial cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute ards respiratory distress syndrome and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung infection prevent: 1
    • acute ards respiratory distress syndrome and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung injury resolution: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome lead and lung damage: 1, 2, 3